I-Mab Reports Third Quarter 2024 Results
November 14, 2024 | 19:00
I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended September 30, 2024.
Mobile Version